6 recruiting, 5 active not recruiting, 3 completed, 3 terminated. 9 Phase 2, 6 Phase 1, 5 Not applicable.
Follow Stage IVB Hepatocellular Carcinoma AJCC v8: new trials by email Literature Review of Stage IVB Hepatocellular Carcinoma AJCC v8 trials Research Report on Stage IVB Hepatocellular Carcinoma AJCC v8
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab Ipilimumab, Nivolumab - BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma | Phase 2 | Terminated | Academic and Community Cancer Research United | 15 | 2023-01-19 | 2026-08-04 |
| Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer Atezolizumab, Cabozantinib, Lenvatinib - Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma | Phase 2 | Recruiting | Academic and Community Cancer Research United | 122 | 2022-05-27 | 2026-08-04 |
| Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax Atezolizumab, Cabozantinib S-malate, Nab-paclitaxel - Advanced Breast Carcinoma, Advanced Endometrial Carcinoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 43 | 2022-04-29 | 2026-07-16 |
| Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant Laboratory Biomarker Analysis, Lenvatinib - Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 2 | Terminated | Emory University | 3 | 2022-04-19 | 2026-04-24 |
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 138 | 2022-03-31 | 2026-08-20 |
| Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma Durvalumab, Hypofractionated Radiation Therapy, Tremelimumab - Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 2 | Recruiting | Mary Feng, MD | 21 | 2022-02-04 | 2025-12-08 |
| Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer Durvalumab, Tremelimumab - BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma | Phase 1 | Active not recruiting | City of Hope Medical Center | 25 | 2021-08-03 | 2026-04-20 |
| Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events Best Practice, Patient Monitoring, Questionnaire Administration - Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8 | Not applicable | Active not recruiting | M.D. Anderson Cancer Center | 750 | 2021-05-12 | 2026-06-16 |
| Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer Fluorouracil, Nivolumab, Recombinant Interferon Alpha 2b-like Protein - Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8 | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 15 | 2021-01-13 | 2026-09-14 |
| Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers Radiation Therapy (RT) - Stage IV Esophageal Adenocarcinoma, Stage IV Esophageal Squamous Cell Carcinoma | Not applicable | Recruiting | University of California, San Francisco | 28 | 2020-08-07 | 2026-08-14 |
| Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver Carboplatin, Paclitaxel, Pevonedistat - Metastatic Cholangiocarcinoma, Metastatic Hepatocellular Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 40 | 2020-03-16 | 2026-10-26 |
| Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D) Computed Tomography, Hepatobiliary Iminodiacetic Acid Scan, Single Photon Emission Computed Tomography - Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8 | Not applicable | Active not recruiting | M.D. Anderson Cancer Center | 42 | 2019-10-10 | 2026-05-22 |
| An Investigational Scan (Magnetic Resonance Elastography) in Detecting Treatment Response in Patients With Advanced Liver Cancer Magnetic Resonance Elastography, Magnetic Resonance Imaging - Advanced Adult Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Not applicable | Completed | M.D. Anderson Cancer Center | 6 | 2019-06-11 | 2025-02-19 |
| IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer Cyclophosphamide, Cytokine-based Biologic Agent IRX-2, Nivolumab - Recurrent Hepatocellular Carcinoma, Refractory Liver Carcinoma | Phase 1 | Active not recruiting | City of Hope Medical Center | 8 | 2019-05-17 | 2026-08-21 |
| BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer IDO1 Inhibitor BMS-986205, Nivolumab - Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 1 / Phase 2 | Terminated | Edward Kim | 8 | 2018-10-16 | 2026-07-29 |
| Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer Nivolumab, Sorafenib - Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8 | Phase 2 | Completed | Robin Kate Kelley | 16 | 2018-04-16 | 2025-02-11 |
| Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma Yttrium Y 90 Glass Microspheres - Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8 | Not applicable | Completed | M.D. Anderson Cancer Center | 299 | 2010-08-04 | 2022-10-14 |
Carcinoma, Hepatocellular (17) · Carcinoma, Renal Cell (2) · Endometrial Neoplasms (2) · Esophageal Neoplasms (2) · Gastrointestinal Neoplasms (2) · Stomach Neoplasms (2) · Adenocarcinoma Of Esophagus (1) · Anal Canal Carcinoma (1) · Anus Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Lobular (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Carcinosarcoma (1)
Adenocarcinoma (17) · Carcinoma (17) · Digestive System Diseases (17) · Digestive System Neoplasms (17) · Liver Diseases (17) · Liver Neoplasms (17) · Neoplasms (17) · Neoplasms by Histologic Type (17) · Neoplasms by Site (17) · Neoplasms, Glandular and Epithelial (17) · Head and Neck Neoplasms (3) · Breast Diseases (2) · Carcinoma, Squamous Cell (2) · Colonic Diseases (2) · Endocrine Gland Neoplasms (2)
Nivolumab (5) · Immunoglobulin G (3) · Cyclophosphamide (2) · Disulfides (2) · Magnetic Resonance Spectroscopy (2) · Taxes (2) · X-Rays (2) · atezolizumab (2) · cabozantinib (2) · durvalumab (2) · lenvatinib (2) · tremelimumab (2) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Biopsy (1)
M.D. Anderson Cancer Center (6) · Academic and Community Cancer Research United (2) · City of Hope Medical Center (2) · Edward Kim (1) · Emory University (1) · Mary Feng, MD (1) · Mayo Clinic (1) · National Cancer Institute (NCI) (1) · Robin Kate Kelley (1) · University of California, San Francisco (1)
United States (17)
Armeen Mahvash (2) · Daneng Li (2) · Mary Feng, MD (2) · Apostolia M Tsimberidou (1) · Dustin A Deming (1) · Edward Kim, MD, PhD (1) · Mehmet Akce (1) · Olumide B. Gbolahan, M.D. (1) · Priya Bhosale (1) · Robin K. Kelley, MD (1) · Ryan W Huey, MD (1) · Sunyoung Lee (1) · Wen Wee Ma (1) · Yanyan Lou, MD, PhD (1)
PMID 34272087, PMID 36821818, PMID 39932259, PMID 41831609
P30CA015083 (2), P30CA016672 (2), P30CA033572 (2), P30CA093373 (1), P30CA138292 (1), U10CA180820 (1)